High Expression of Multidrug Resistance-1 (MDR-1) and its Relationship with Multiple Prognostic Factors in Gastric Carcinomas in Patients in Turkey

Drug resistance remains a major problem in the treatment of gastric cancer. In Turkey, gastric carcinoma is the second most common cancer and, because the rate of early diagnosis is low, chemotherapy plays an important role in the treatment of the disease. We aimed to investigate expression of the multidrug resistance-1 gene (MDR-1) and its relationship with multiple prognostic factors in gastric cancers. Between 1996 and 1998, a total of 55 patients (37 men and 19 women; median age 55 years) were studied. Sections from specimens of gastric carcinomas were immunohistochemically stained to detect P-glycoprotein (which is associated with MDR-1 expression). We found MDR-1 expression in 48 (87%) of the patients. None of the multiple prognostic factors, including histological type of tumour, correlated with expression of MDR-1. Patients who had low MDR-1 expression had better survival. We conclude that the expression of MDR-1 in gastric cancer is high in Turkey, and this may be related to poor prognosis.

[1]  S. Kitano,et al.  Pathology and prognosis of gastric carcinoma , 2000, Cancer.

[2]  C. Shun,et al.  Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. , 1998, Journal of clinical gastroenterology.

[3]  E. Dolar,et al.  The epidemiology of gastrointestinal cancer in Turkey: a review of our accumulated experience. , 1996, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[4]  R. Pirker,et al.  MDR1 gene expression and its clinical relevance in primary gastric carcinomas , 1993, Cancer.

[5]  Necati Örmeci,et al.  Early Stomach Cancer in Turkey , 1993 .

[6]  T. Yao,et al.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy , 1992, Cancer.

[7]  T. Wobbes,et al.  Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. , 1992, Gastroenterology.

[8]  T. Tsuruo,et al.  Reactivity of P-glycoprotein monoclonal antibodies in childhood cancers. , 1992, Oncology.

[9]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[10]  Y. Kodera,et al.  Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. , 1992, European journal of cancer.

[11]  J. Ajani,et al.  Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. , 1991, Archives of Pathology & Laboratory Medicine.

[12]  P. Borst,et al.  Multidrug resistance mediated by P-glycoproteins. , 1991, Seminars in cancer biology.

[13]  P. Meltzer,et al.  Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[14]  P. Brousset,et al.  Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. , 1990, British Journal of Cancer.

[15]  J. Bruner,et al.  Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. , 1990, American journal of clinical pathology.

[16]  M C Willingham,et al.  Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[18]  Douglass Ho,et al.  Gastric adenocarcinoma--management of the primary disease. , 1985 .

[19]  B. Hankey,et al.  Evaluation of AJC stomach cancer staging using the SEER population. , 1985, Seminars in oncology.

[20]  I. Selikoff,et al.  Epidemiology of gastrointestinal cancer , 1974, Environmental health perspectives.

[21]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.